Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk securities between November 2, 2022, and December 19, 2024, about the upcoming lead plaintiff deadline of March 25, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 25, 2025 [2]. - The lawsuit claims that during the class period, defendants made misleading statements regarding the phase 3 CagriSema study on obesity, particularly about the expected outcomes and the trial protocol [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Investors have the option to select their counsel or remain absent from the class without affecting their ability to share in any potential recovery [6].

Group 1 - The Rosen Law Firm is reminding purchasers of FMC Corporation securities from November 16, 2023, to February 4, 2025, about the April 14, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased FMC securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lawsuit alleges that FMC made false and misleading statements regarding its channel management initiatives and pricing strategies, leading to inflated inventory levels in various regions [4] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [3] - The lawsuit claims that when the true details about FMC's business practices were revealed, investors suffered damages due to the misleading statements made by the defendants [4]

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. SO WHAT: If you purchased Ready Capital securities during ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Edison International securities between February 25, 2021, and February 6, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Edison securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2025 [3] - The lawsuit alleges that Edison made materially false and misleading statements regarding its Public Safety Power Shutoffs program, which purportedly increased fire risk and legal exposure [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased TELUS International securities between February 16, 2023, and August 1, 2024, of the March 31, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased TELUS International securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is March 31, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Case Allegations - The lawsuit alleges that TELUS International failed to disclose that its AI Data Solutions offerings cannibalized higher-margin products, leading to declining profitability [5]. - It is claimed that the shift towards AI increased pressure on the company's margins more than previously disclosed, resulting in misleading positive statements about the company's business and prospects [5].

Core Insights - Amgen and Kyowa Kirin announced positive results from the ROCKET Phase 3 clinical trial program for rocatinlimab, a T-cell rebalancing therapy for moderate to severe atopic dermatitis [1][2] Study Results - The IGNITE study demonstrated that both dose strengths of rocatinlimab met co-primary and key secondary endpoints, showing statistical significance against placebo [2] - At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction in Eczema Area and Severity Index (EASI-75), a 29.5% improvement over placebo (p < 0.001) [3] - In the lower dose group, 36.3% achieved EASI-75, a 23.4% improvement over placebo (p < 0.001) [3] - For the validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™), 23.6% of the higher dose group achieved a score of 0 or 1, a 14.9% difference from placebo (p < 0.001) [4] - The lower dose group had 19.1% achieving this endpoint, a 10.3% difference from placebo (p = 0.002) [4] - The revised Investigator's Global Assessment (rIGA™) score of 0/1 was achieved by 22.7% of the higher dose group, a 14.4% difference from placebo (p < 0.001) [5] - In the lower dose group, 16.3% achieved this endpoint, an 8.0% difference from placebo (p = 0.01) [5] Safety Profile - Safety findings were consistent with previous observations, with common treatment-emergent adverse events including pyrexia, chills, and headache [6] - Gastrointestinal ulceration events were reported in a higher number of patients receiving rocatinlimab compared to placebo, with an overall incidence of less than 1% [6] Future Trials - The ASCEND trial will investigate the long-term effects of rocatinlimab beyond 24 weeks, including maintenance of clinical response [6] - The ASTRO and ORBIT trials will evaluate rocatinlimab in adolescent patients [6] Additional Studies - The SHUTTLE study also met its co-primary endpoints, showing significant efficacy for rocatinlimab in combination with topical corticosteroids [7] - In SHUTTLE, 52.3% of patients in the higher dose group achieved EASI-75, a 28.7% difference from placebo (p < 0.001) [7] - The VOYAGER study confirmed that rocatinlimab does not interfere with responses to certain vaccinations [9] About Rocatinlimab - Rocatinlimab is an anti-OX40 human monoclonal antibody targeting T-cell imbalance in atopic dermatitis and other conditions [13] - It is being studied for multiple indications, including moderate to severe uncontrolled asthma and prurigo nodularis [13]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Newmont Corporation securities between February 22, 2024, and October 23, 2024, of the April 1, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Newmont securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The lawsuit alleges that Newmont provided misleading statements regarding its ability to increase gold production and reduce costs, which led to investor damages when the truth was revealed [4]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 25, 2025 [1] Group 1: Class Action Details - Investors who purchased ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lawsuit claims that ESSA Pharma Inc. misled investors regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer, overstating its clinical and commercial prospects [5] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 25, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is March 25, 2025, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Allegations - The lawsuit alleges that ESSA Pharma Inc. failed to disclose critical information regarding the efficacy of masofaniten in combination with enzalutamide, leading to misleading public statements [4]. - Specific claims include that the combination treatment had no clear efficacy benefit over enzalutamide alone and was less effective in treating prostate cancer than previously stated [4]. - The lawsuit asserts that the M-E Combination Study was unlikely to meet its primary endpoint, resulting in overstated clinical and commercial prospects for masofaniten [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Alarum Technologies Ltd. securities, alleging that the company made false and misleading statements regarding its business performance during the specified Class Period from March 14, 2024, to August 26, 2024 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Alarum was less effective in retaining and expanding customer engagements than it had represented, which impaired its ability to generate consistent revenue growth [5]. - The lawsuit asserts that Alarum's business and financial prospects were overstated, leading to materially false and misleading public statements [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by April 15, 2025, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].